Acute myeloid leukemia: Therapy resistance and a potential role for tetraspanin membrane scaffolds

Floren, Muskan; Gillette, Jennifer M.

doi:10.1016/j.biocel.2021.106029

Cited by 12 publications

(12 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sorafenib, a vascular endothelial growth factor (VEGF) inhibitor, is a first-line agent for treating hepatocellular carcinoma, and its monotherapy has become the standard systemic therapy for advanced cases. Strong correlations have been observed between the levels of Tspan24 in hepatocellular carcinoma cells and resistance to sorafenib [ 118 ]. Tspan28-positive AML (Acute myeloid leukemia) cells are 30–50% more resistant to conventional chemotherapy, and Tspan29 has also been shown to regulate the development of leukemogenesis and resistance to chemotherapy.…”

Section: The Role Of the Tspan Protein Family In Cancer Treatmentmentioning

confidence: 99%

“…Tspan28-positive AML (Acute myeloid leukemia) cells are 30–50% more resistant to conventional chemotherapy, and Tspan29 has also been shown to regulate the development of leukemogenesis and resistance to chemotherapy. Tspan29-positive AML cells are more likely than Tspan29-negative AML cells are more resistant and migratory to Ara-C chemotherapy [ 118 ]. Tspan3 has been shown to be upregulated in both adriamycin-resistant AML samples and cell lines [ 118 ].…”

Section: The Role Of the Tspan Protein Family In Cancer Treatmentmentioning

confidence: 99%

“…Tspan29-positive AML cells are more likely than Tspan29-negative AML cells are more resistant and migratory to Ara-C chemotherapy [ 118 ]. Tspan3 has been shown to be upregulated in both adriamycin-resistant AML samples and cell lines [ 118 ]. In the tumor microenvironment, Tspan29 is responsible for the crosstalk between BMMSCs (bone marrow mesenchymal stem cells) and breast cancer cells, which leads to chemoresistance [ 119 ].…”

Section: The Role Of the Tspan Protein Family In Cancer Treatmentmentioning

confidence: 99%

See 2 more Smart Citations

Tspan protein family: focusing on the occurrence, progression, and treatment of cancer

Zhang,

Song,

Shang

et al. 2024

Cell Death Discov.

View full text Add to dashboard Cite

The Tetraspanins (Tspan) protein family, also known as the tetraspanin family, contains 33 family members that interact with other protein molecules such as integrins, adhesion molecules, and T cell receptors by forming dimers or heterodimers. The Tspan protein family regulates cell proliferation, cell cycle, invasion, migration, apoptosis, autophagy, tissue differentiation, and immune response. More and more studies have shown that Tspan proteins are involved in tumorigenesis, epithelial-mesenchymal transition, thrombosis, tumor stem cell, and exosome signaling. Some drugs and microRNAs can inhibit Tspan proteins, thus providing new strategies for tumor therapy. An in-depth understanding of the functions and regulatory mechanisms of the Tspan protein family, which can promote or inhibit tumor development, will provide new strategies for targeted interventions in the future.

show abstract

Section: The Role Of the Tspan Protein Family In Cancer Treatmentmentioning

confidence: 99%

Section: The Role Of the Tspan Protein Family In Cancer Treatmentmentioning

confidence: 99%

Section: The Role Of the Tspan Protein Family In Cancer Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Tspan protein family: focusing on the occurrence, progression, and treatment of cancer

Zhang,

Song,

Shang

et al. 2024

Cell Death Discov.

View full text Add to dashboard Cite

show abstract

“…They are particularly adapted to the treatment of colorectal cancer, hepatocellular carcinoma, gastric cancer and other types of solid tumors [ 6 , 7 , 8 , 9 ]. These proteins are also considered in onco-hematology, notably for the treatment of acute myeloid leukemia (AML) and lymphoma [ 10 ]. For example, tetraspanin CD37 is expressed prominently on the surface of B cells and is chiefly implicated in the aggressivity of B-cell lymphoma [ 11 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

Targeting of Tetraspanin CD81 with Monoclonal Antibodies and Small Molecules to Combat Cancers and Viral Diseases

Bailly

Thuru

2023

Cancers

View full text Add to dashboard Cite

Tetraspanin CD81 plays major roles in cell-cell interactions and the regulation of cellular trafficking. This cholesterol-embarking transmembrane protein is a co-receptor for several viruses, including HCV, HIV-1 and Chikungunya virus, which exploits the large extracellular loop EC2 for cell entry. CD81 is also an anticancer target implicated in cancer cell proliferation and mobility, and in tumor metastasis. CD81 signaling contributes to the development of solid tumors (notably colorectal, liver and gastric cancers) and has been implicated in the aggressivity of B-cell lymphomas. A variety of protein partners can interact with CD81, either to regulate attachment and uptake of viruses (HCV E2, claudin-1, IFIM1) or to contribute to tumor growth and dissemination (CD19, CD44, EWI-2). CD81-protein interactions can be modulated with molecules targeting the extracellular domain of CD81, investigated as antiviral and/or anticancer agents. Several monoclonal antibodies anti-CD81 have been developed, notably mAb 5A6 active against invasion and metastasis of triple-negative breast cancer cells. CD81-EC2 can also be targeted with natural products (trachelogenin and harzianoic acids A-B) and synthetic compounds (such as benzothiazole-quinoline derivatives). They are weak CD81 binders but offer templates for the design of new compounds targeting the open EC2 loop. There is no anti-CD81 compound in clinical development at present, but this structurally well-characterized tetraspanin warrants more substantial considerations as a drug target.

show abstract

“…Several mechanisms of drug resistance in AML have been identified. However, clinical trials of treatments targeting these mechanisms have been unsuccessful 1,2 . In recent years, it has been known that the bone marrow microenvironment plays a critical role in AML progression.…”

Section: Introductionmentioning

confidence: 99%

Acute myeloid leukemia (AML)‐derived mesenchymal stem cells induce chemoresistance and epithelial–mesenchymal transition‐like program in AML through IL‐6/JAK2/STAT3 signaling

Dong

Zhang

et al. 2023

Cancer Science

View full text Add to dashboard Cite

Acute myeloid leukemia (AML) has a high rate of treatment failure due to increased prevalence of therapy resistance. Mesenchymal stem cells (MSCs) in the leukemia microenvironment contribute to chemoresistance in AML, but the specific mechanism remains unclear. The critical role of the epithelial-mesenchymal transition (EMT)-like profile in AML chemoresistance has been gradually recognized. However, there is no research to suggest that the AML-derived bone marrow mesenchymal stem cells

show abstract

Acute myeloid leukemia: Therapy resistance and a potential role for tetraspanin membrane scaffolds

Cited by 12 publications

References 29 publications

Tspan protein family: focusing on the occurrence, progression, and treatment of cancer

Tspan protein family: focusing on the occurrence, progression, and treatment of cancer

Targeting of Tetraspanin CD81 with Monoclonal Antibodies and Small Molecules to Combat Cancers and Viral Diseases

Acute myeloid leukemia (AML)‐derived mesenchymal stem cells induce chemoresistance and epithelial–mesenchymal transition‐like program in AML through IL‐6/JAK2/STAT3 signaling

Contact Info

Product

Resources

About